ID   PANC-1/Gem
AC   CVCL_C0WS
SY   PANC-1/GEM
DR   cancercelllines; CVCL_C0WS
DR   Wikidata; Q114312645
RX   PubMed=31410021;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0480 ! PANC-1
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31410021; DOI=10.2147/OTT.S208924;
RA   Wang B.-L., Shen C., Li Y., Zhang T., Huang H., Ren J., Hu Z.-J., Xu J.,
RA   Xu B.;
RT   "Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by
RT   regulating GST pi and LRP/1 ERK/JNK signalling.";
RL   Onco Targets Ther. 12:5751-5765(2019).
//